Fidelity Medical
This article was originally published in The Gray Sheet
Executive Summary
Agrees to file consent with the Securities and Exchange Commission "to the entry of a permanent injunction against violations of certain anti-fraud, periodic reporting, record- keeping and internal accounting control provisions of the federal securities laws," the marketer of electronic systems for medical imaging and cardiodiagnosis announces March 28. The agreement, which concludes an SEC investigation into Fidelity's revenue recognition practices under prior management up until May 1992 ("The Gray Sheet" Aug. 24, 1992, p. 11), is neither admission nor denial by Fidelity of SEC's allegations, the firm states. The permanent injunction is expected "within the next several weeks"
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.